<DOC>
	<DOC>NCT02808429</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, dose response and efficacy of atacicept in patients with IgA nephropathy and persistent proteinuria. The study hypothesis is that treatment with atacicept will reduce proteinuria compared to placebo.</brief_summary>
	<brief_title>Efficacy and Safety of Atacicept in IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<criteria>Greater than or equal to (&gt;=)18 years of age Biopsyproven Immunoglobulin (IgA) nephropathy Proteinuria 1 to 6 grams per day (g/day) Stable and optimal dose of Angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blockers (ARB) at least 8 weeks prior to screening Concomitant significant renal disease other than IgA nephropathy IgA nephropathy with significant glomerulosclerosis or cortical scarring Diagnosis of HenochSchonlein purpura Failure to meet estimated glomerular filtration rate (eGFR) and biopsy requirement criteria Serum IgG below 6 grams per liter (g/L) Use of cyclophosphamide ever or use of other immunosuppressants or systemic corticosteroids within 4 months Active infection requiring hospitalization or treatment with parenteral antiinfectives within 4 weeks History, or current diagnosis, of active tuberculosis (TB), or untreated latent TB infection History of or positive HIV and/or positive for hepatitis B or Hepatitis C at screening History of malignancy Nursing or pregnancy Any condition, including any uncontrolled disease state other than IgA nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atacicept</keyword>
	<keyword>IgA Nephropathy</keyword>
	<keyword>BergerÂ´s disease</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Proteinuria</keyword>
</DOC>